Pharmaceutical Executive May 11, 2021
Andy Studna

Launching a big pharma biotech incubator during the pandemic.

Imagine being tasked with opening a business in the past calendar year; a year that has been derailed by a global pandemic. For Sally Allain, head of Johnson & Johnson Innovation – JLABS @ Washington, DC, it hasn’t been a fictional story. Tabbed to lead Johnson & Johnson Innovation’s newest JLABS location in the nation’s capital, opening its doors this spring, Allain has earned her latest opportunity through years of hard work in the pharmaceutical industry.

Local to the D.C. area, Allain is a graduate of Virginia Tech, where she earned her BS in Microbiology as well as her MS in Microbiology and Immunology. She also holds an MBA from the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma, Pharma / Biotech, Technology, Trends
Former Bristol Myers CEO tapped as Novartis’ next board chair
The Power of Drug Discovery with Philip Tagari
Novartis raises forecasts as top drug sales beat Wall Street estimates
Pharma Pulse 4/23/24: Drug Discount Programs Poised to Change with New Tech, SpecialtyRx Savings Navigator to Enhance Affordability & more
AI Ushers in HPC Revival Says TACC’s Dan Stanzione

Share This Article